About this trial
This is an observational study, looking at the effect HIV treatment has on the health of our heart. The investigators are comparing how well cholesterol is processed by those not on therapy with those who are on treatment. They are also comparing those on NNRTI-based regimens with those on PI- based ones.
Background information
Cardiovascular disease is increasingly recognized to be a significant cause of morbidity and mortality among people with chronic HIV infection in the current era of effective antiretroviral therapy. Those treated with antiretroviral therapy have increased traditional cardiovascular risk factors, but whether HIV infection in and of itself confers a significant increase in cardiovascular risk is largely unknown.
| Official title: | Impact of HIV Infection and Treatment With Highly Active Antiretroviral Therapy on Reverse Cholesterol Transport |
|---|---|
| What is this trial studying? | Side effect management |
| Start date: | June 2005 This may be the proposed or expected start date for trials which have not yet started. |
| How many participants will this trial enrol? | 75 The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic. |
| Who can enrol in this trial? | You may be eligible to participate in this trial if you meet the following criteria:
|
| Links to further information: | |
| Keywords: | cardiovascular disease |
If you are interested in enrolling in this trial
Before making the decision to participate in any clinical trial, NAPWA recommends that you discuss the potential benefits and risks of participation with your treating doctor. Your doctor can also provide advice about your eligibility to participate in the trial.
- You can print this page to take it with you to the doctor – just use your browser's 'print' function.
- Before making the decision to participate in any clinical research, read our background information.
- Email NAPWA if you have any questions or comments about this trial
- Call the Treataware info line if you need further advice